Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar.
http://www.fiercebiotech.com/story/lillys-ceo-keeps-faith-pipeline-biotech-gets-too-expensive/2015-08-14?utm_medium=rss&utm_source=feedly&utm_campaign=rss
No comments:
Post a Comment